Skip to main content
SpringerLink
Log in
Book cover

Transgender Medicine pp 239–281Cite as

HIV Infection in Transgender Persons

  • Chapter
  • First Online:

  • 1725 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Transgender persons are disproportionately affected by HIV compared to the general population. In this chapter, we hope to shed light on the true burden of HIV on this marginalized population. We will review the factors that contribute to the high prevalence of HIV among transgender persons, in particular, high-risk sexual behaviors and substance abuse. Additionally, we will discuss the unique socioeconomic and psychosocial barriers that predispose this population to poor outcomes related to HIV prevention and treatment. We will also explain the contribution of transphobia in healthcare systems to the poor outcomes across the continuum of HIV care. This chapter will highlight challenges for transgender persons living with HIV, and attempt to offer solutions to overcome some of the obstacles. The choice of antiretroviral therapy with concomitant use of gender-affirming therapies will be discussed in detail.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. UNAIDS. Global factsheet. 2016. http://aidsinfo.unaids.org/. Accessed Feb 2018.

  2. CDC. HIV surveillance. 2018. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html/.

  3. Reisner SL, Murchison GR. A global research synthesis of HIV and STI biobehavioural risks in female-to-male transgender adults. Glob Public Health. 2016;11(7–8):866–87.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Clark H, Babu AS, Wiewel EW, Opoku J, Crepaz N. Diagnosed HIV infection in transgender adults and adolescents: results from the national HIV surveillance system, 2009–2014. AIDS Behav. 2017;21(9):2774–83.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12(1):1–17.

    Article  PubMed  Google Scholar 

  6. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012;380(9839):367–77.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S210–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.

    Article  PubMed  Google Scholar 

  9. Salazar LF, Crosby RA, Jones J, Kota K, Hill B, Masyn KE. Contextual, experiential, and behavioral risk factors associated with HIV status: a descriptive analysis of transgender women residing in Atlanta, Georgia. Int J STD AIDS. 2017;28(11):1059–66.

    Article  PubMed  Google Scholar 

  10. Poteat T, Ackerman B, Diouf D, et al. HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: a cross-sectional analysis. PLoS Med. 2017;14(11):e1002422.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chhim S, Ngin C, Chhoun P, et al. HIV prevalence and factors associated with HIV infection among transgender women in Cambodia: results from a national integrated biological and behavioral survey. BMJ Open. 2017;7(8):e015390.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Scheim AI, Bauer GR, Travers R. HIV-related sexual risk among transgender men who are gay, bisexual, or have sex with men. J Acquir Immune Defic Syndr. 2017;74(4):e89–96.

    Article  PubMed  Google Scholar 

  13. Reisner SL, White Hughto JM, Pardee D, Sevelius J. Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males. Int J STD AIDS. 2016;27(11):955–66.

    Article  PubMed  Google Scholar 

  14. Stephens SC, Bernstein KT, Philip SS. Male to female and female to male transgender persons have different sexual risk behaviors yet similar rates of STDs and HIV. AIDS Behav. 2011;15(3):683–6.

    Article  PubMed  Google Scholar 

  15. Hygiene NDoHaM. HIV among people identified as transgender in New York City, 2012–2016. 2016. https://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-aids-in-msm.pdf. Accessed Feb 2018.

  16. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39(4):1048–63.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr. 2010;53(4):537–43.

    Article  PubMed  Google Scholar 

  18. Poteat T, German D, Flynn C. The conflation of gender and sex: gaps and opportunities in HIV data among transgender women and MSM. Glob Public Health. 2016;11(7–8):835–48.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Melendez RM, Pinto R. ‘It’s really a hard life’: love, gender and HIV risk among male-to-female transgender persons. Cult Health Sex. 2007;9(3):233–45.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gama A, Martins MRO, Mendão L, Barros H, Dias S. HIV infection, risk factors and health services use among male-to-female transgender sex workers: a cross-sectional study in Portugal. AIDS Care. 2018;30(1):1–8.

    Article  PubMed  Google Scholar 

  21. Salas-Espinoza KJ, Menchaca-Diaz R, Patterson TL, et al. HIV prevalence and risk behaviors in male to female (MTF) transgender persons in Tijuana, Mexico. AIDS Behav. 2017;21(12):3271–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Siembida EJ, Eaton LA, Maksut JL, Driffin DD, Baldwin R. A comparison of HIV-related risk factors between black transgender women and black men who have sex with men. Transgender Health. 2016;1(1):172–80.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Levine WC, Pope V, Bhoomkar A, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis. 1998;177(1):167–74.

    Article  CAS  PubMed  Google Scholar 

  24. Wormser GP, Krupp LB, Hanrahan JP, Gavis G, Spira TJ, Cunningham-Rundles S. Acquired immunodeficiency syndrome in male prisoners. New insights into an emerging syndrome. Ann Intern Med. 1983;98(3):297–303.

    Article  CAS  PubMed  Google Scholar 

  25. Brennan J, Kuhns LM, Johnson AK, et al. Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization. Am J Public Health. 2012;102(9):1751–7.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Reisner SL, Bailey Z, Sevelius J. Racial/ethnic disparities in history of incarceration, experiences of victimization, and associated health indicators among transgender women in the U.S. Women Health. 2014;54(8):750–67.

    Article  Google Scholar 

  27. Clements-Nolle K, Marx R, Guzman R, Katz M. HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention. Am J Public Health. 2001;91(6):915–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Flores AR, Brown TNT, Herman JL. Adults who identify as transgender are more racially and ethnically diverse than the U.S. general population. Los Angeles, CA: The Williams Institute; 2016.

    Google Scholar 

  29. Reisner SL, Biello KB, White Hughto JM, et al. Psychiatric diagnoses and comorbidities in a diverse, multicity cohort of young transgender women: baseline findings from project lifeskills. JAMA Pediatr. 2016;170(5):481–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1987;1(2):67–76.

    CAS  PubMed  Google Scholar 

  31. Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6):815–26.

    Article  PubMed  Google Scholar 

  32. Denson DJ, Padgett PM, Pitts N, et al. Health care use and HIV-related behaviors of Black and Latina transgender women in 3 US metropolitan areas: results from the transgender HIV behavioral survey. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S268–75.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Braun HM, Candelario J, Hanlon CL, et al. Transgender women living with HIV frequently take antiretroviral therapy and/or feminizing hormone therapy differently than prescribed due to drug-drug interaction concerns. LGBT Health. 2017;4(5):371–5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mizuno Y, Frazier EL, Huang P, Skarbinski J. Characteristics of transgender women living with HIV receiving medical care in the United States. LGBT Health. 2015;2(3):228–34.

    Article  PubMed  Google Scholar 

  35. Sevelius JM, Saberi P, Johnson MO. Correlates of antiretroviral adherence and viral load among transgender women living with HIV. AIDS Care. 2014;26(8):976–82.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lemons A, Beer L, Finlayson T, McCree DH, Lentine D, Shouse RL. Characteristics of HIV-positive transgender men receiving medical care: United States, 2009–2014. Am J Public Health. 2018;108(1):128–30.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kalichman SC, Hernandez D, Finneran S, Price D, Driver R. Transgender women and HIV-related health disparities: falling off the HIV treatment cascade. Sex Health. 2017;14(5):469–76.

    Article  PubMed  Google Scholar 

  38. Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423–41.

    Article  PubMed  Google Scholar 

  39. Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol. 2013;68(4):197–209.

    Article  Google Scholar 

  40. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America—forgotten but not gone. N Engl J Med. 2010;362(11):967–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Fletcher JB, Kisler KA, Reback CJ. Housing status and HIV risk behaviors among transgender women in Los Angeles. Arch Sex Behav. 2014;43(8):1651–61.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nuttbrock L, Hwahng S, Bockting W, et al. Lifetime risk factors for HIV/sexually transmitted infections among male-to-female transgender persons. J Acquir Immune Defic Syndr. 2009;52(3):417–21.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Conron KJ, Scott G, Stowell GS, Landers SJ. Transgender health in Massachusetts: results from a household probability sample of adults. Am J Public Health. 2012;102(1):118–22.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Dowshen N, Matone M, Luan X, et al. Behavioral and health outcomes for HIV+ young transgender women (YTW) linked to and engaged in medical care. LGBT Health. 2016;3(2):162–7.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Santos GM, Wilson EC, Rapues J, Macias O, Packer T, Raymond HF. HIV treatment cascade among transgender women in a San Francisco respondent driven sampling study. Sex Transm Infect. 2014;90(5):430–3.

    Article  PubMed  Google Scholar 

  46. Palazzolo SL, Yamanis TJ, De Jesus M, Maguire-Marshall M, Barker SL. Documentation status as a contextual determinant of HIV risk among young transgender Latinas. LGBT Health. 2016;3(2):132–8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Frost DM, Lehavot K, Meyer IH. Minority stress and physical health among sexual minority individuals. J Behav Med. 2015;38(1):1–8.

    Article  PubMed  Google Scholar 

  48. Grossman AH, D’Augelli AR. Transgender youth and life-threatening behaviors. Suicide Life Threat Behav. 2007;37(5):527–37.

    Article  PubMed  Google Scholar 

  49. Budge SL, Adelson JL, Howard KA. Anxiety and depression in transgender individuals: the roles of transition status, loss, social support, and coping. J Consult Clin Psychol. 2013;81(3):545–57.

    Article  PubMed  Google Scholar 

  50. Blank MB, Himelhoch SS, Balaji AB, et al. A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health. 2014;104(12):2377–84.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Clements-Nolle K, Marx R, Katz M. Attempted suicide among transgender persons: the influence of gender-based discrimination and victimization. J Homosex. 2006;51(3):53–69.

    Article  PubMed  Google Scholar 

  52. McCabe SE, West BT, Hughes TL, Boyd CJ. Sexual orientation and substance abuse treatment utilization in the United States: results from a national survey. J Subst Abuse Treat. 2013;44(1):4–12.

    Article  PubMed  Google Scholar 

  53. Medley G, Lipari RN, Bose J, Cribb DS, Kroutil LA, McHenry G. Sexual orientation and estimates of adult substance use and mental health: results from the 2015 national survey on drug use and health. Substance Abuse and Mental Health Services Administration; 2016.

    Google Scholar 

  54. Dale SK, Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV. J Health Psychol. 2016;21(7):1311–21.

    Article  PubMed  Google Scholar 

  55. Kosenko K, Rintamaki L, Raney S, Maness K. Transgender patient perceptions of stigma in health care contexts. Med Care. 2013;51(9):819–22.

    Article  PubMed  Google Scholar 

  56. Cruz TM. Assessing access to care for transgender and gender nonconforming people: a consideration of diversity in combating discrimination. Soc Sci Med. 2014;110:65–73.

    Article  PubMed  Google Scholar 

  57. Lacombe-Duncan A. An intersectional perspective on access to HIV-related healthcare for transgender women. Transgender Health. 2016;1(1):137–41.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Stotzer RL, Silverschanz P, Wilson A. Gender identity and social services: barriers to care. J Soc Serv Res. 2013;39(1):63–77.

    Article  Google Scholar 

  59. Kattari SK, Walls NE, Whitfield DL, Langenderfer Magruder L. Racial and ethnic differences in experiences of discrimination in accessing social services among transgender/gender-nonconforming people. J Ethn Cult Divers Soc Work. 2017;26(3):217–35.

    Article  Google Scholar 

  60. Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of transgender-related discrimination and implications for health: results from the Virginia transgender health initiative study. Am J Public Health. 2013;103(10):1820–9.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Andrasik MP, Yoon R, Mooney J, et al. Exploring barriers and facilitators to participation of male-to-female transgender persons in preventive HIV vaccine clinical trials. Prev Sci. 2014;15(3):268–76.

    Article  PubMed  Google Scholar 

  62. Ganju D, Saggurti N. Stigma, violence and HIV vulnerability among transgender persons in sex work in Maharashtra, India. Cult Health Sex. 2017;19(8):903–17.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Cook CL, Canidate S, Ennis N, Cook RL. Types and delivery of emotional support to promote linkage and engagement in HIV care. Patient Prefer Adherence. 2018;12:45–52.

    Article  PubMed  Google Scholar 

  64. Kelly JD, Hartman C, Graham J, Kallen MA, Giordano TP. Social support as a predictor of early diagnosis, linkage, retention, and adherence to HIV care: results from the steps study. J Assoc Nurses AIDS Care. 2014;25(5):405–13.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Klein A, Golub SA. Family rejection as a predictor of suicide attempts and substance misuse among transgender and gender nonconforming adults. LGBT Health. 2016;3(3):193–9.

    Article  PubMed  Google Scholar 

  66. Rebchook G, Keatley J, Contreras R, et al. The transgender women of color initiative: implementing and evaluating innovative interventions to enhance engagement and retention in HIV care. Am J Public Health. 2017;107(2):224–9.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Dasarathan S, Kalaivani S. Study of prevalence of sexually transmitted infections/human immunodeficiency virus and condom use among male-to-female transgender: a retrospective analysis from a tertiary care hospital in Chennai. Indian J Sex Transm Dis. 2017;38(1):43–6.

    Article  Google Scholar 

  68. Keshinro B, Crowell TA, Nowak RG, et al. High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. J Int AIDS Soc. 2016;19(1):21270.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Green N, Hoenigl M, Morris S, Little SJ. Risk behavior and sexually transmitted infections among transgender women and men undergoing community-based screening for acute and early HIV infection in San Diego. Med (Baltimore). 2015;94(41):e1830.

    Article  Google Scholar 

  70. Pickering JM, Whitworth JA, Hughes P, et al. Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. Sex Transm Infect. 2005;81(6):488–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Hope-Rapp E, Anyfantakis V, Fouéré S, et al. Etiology of genital ulcer disease. A prospective study of 278 cases seen in an STD clinic in Paris. Sex Transm Dis. 2010;37(3):153–8.

    Article  PubMed  Google Scholar 

  72. McFarland W, Wilson EC, Raymond HF. HIV prevalence, sexual partners, sexual behavior and HIV acquisition risk among trans men, San Francisco, 2014. AIDS Behav. 2017;21(12):3346–52.

    Article  PubMed  Google Scholar 

  73. CDC. Special populations—2015 STD treatment guidelines. 2015. https://www.cdc.gov/std/tg2015/specialpops.htm.

  74. WHO. Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people. WHO; 2011. http://www.who.int/hiv/pub/guidelines/msm_guidelines2011/en/.

  75. Sevelius J. “There’s no pamphlet for the kind of sex I have”: HIV-related risk factors and protective behaviors among transgender men who have sex with nontransgender men. J Assoc Nurses AIDS Care. 2009;20(5):398–410.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Reisner SL, Perkovich B, Mimiaga MJ. A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men. AIDS Patient Care STDS. 2010;24(8):501–13.

    Article  PubMed  PubMed Central  Google Scholar 

  77. CDC. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae. MMWR Recomm Rep. 2014;63(RR02):1–19.

    Google Scholar 

  78. Garg STL, Grasso C, Mayer KH. Prevalent and incident hepatitis C infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis. 2013;56(10):1480–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012;55(2):279–90.

    Article  PubMed  PubMed Central  Google Scholar 

  80. CDC. Guidelines for viral hepatitis surveillance and case management. 2005.

    Google Scholar 

  81. CDC. Viral hepatitis—2015 STD treatment guidelines. 2018. https://www.cdc.gov/std/tg2015/hepatitis.htm.

  82. AIDSinfo. Pre-exposure prophylaxis (PrEP) understanding HIV/AIDS. 2018. https://www.ncbi.nlm.nih.gov/pubmed/. Accessed Feb 2018.

  83. AIDSinfo. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2018. https://aidsinfo.nih.gov/news/1254/fda-approves-first-drug-for-reducing-the-risk-of-sexually-acquired-hiv-infection.

  84. CDC. FDA approves drug for HIV prevention. 2018. https://www.cdc.gov/nchhstp/newsroom/2012/fda-approvesdrugstatement.html. Accessed Feb 2018.

  85. CDC. Preexposure prophylaxis for the prevention of HIV in the United States—2014: a clinical practice guideline. 2014. https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed Feb 2018.

  86. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med. 2017;376(5):501–2.

    Article  PubMed  Google Scholar 

  90. Mascolini M. Infection with multidrug-resistant HIV while adherent to TDF/FTC PrEP. Chicago, IL: HIV Research for Prevention; 2016.

    Google Scholar 

  91. Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11(7–8):1060–75.

    Article  PubMed  Google Scholar 

  92. CHRP. UCSD: PrEP linkage adherence & pharmacology in transgender persons. 2018. http://www.californiaaidsresearch.org/files/award-abstracts/prevention-and-linkage-to-care/ucsd-prep-trans.html.

  93. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy. 2009;29(8):924–9.

    Article  CAS  PubMed  Google Scholar 

  94. Anderson PL, Reirden D, Castillo-Mancilla J. Pharmacologic considerations for preexposure prophylaxis in transgender women (1999). J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S230–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO. 2015.

    Google Scholar 

  96. Gilead. Truvada prescribing information package insert. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021752s047lbl.pdf. Accessed Feb 2018.

  97. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19(7 Suppl 6):21105.

    Google Scholar 

  98. Institute NA. PrEP to prevent HIV acquisition guideline—AIDS institute clinical guidelines. 2017. https://www.hivguidelines.org/prep-for-prevention/prep-to-prevent-hiv/.

  99. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582–92.

    Article  CAS  PubMed  Google Scholar 

  100. Poteat T, Malik M, Scheim A, Elliott A. HIV prevention among transgender populations: knowledge gaps and evidence for action. Curr HIV/AIDS Rep. 2017;14(4):141–52.

    Article  PubMed  PubMed Central  Google Scholar 

  101. CDC. 2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens. 2018. https://stacks.cdc.gov/view/cdc/50872/cdc_DS1_50872.pdf.

  102. Institute NA. Discontinuing PrEP. 2017.

    Google Scholar 

  103. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005;54(RR-2):1–20.

    Google Scholar 

  104. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337(21):1485–90.

    Article  CAS  Google Scholar 

  105. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875–92.

    Article  PubMed  Google Scholar 

  106. CDC. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV. Atlanta, GA; 2016.

    Google Scholar 

  107. Institute NA. PEP for non-occupational exposure to HIV guideline—AIDS institute clinical guidelines. 2014. https://www.hivguidelines.org/pep-for-hiv-prevention/non-occupational/.

  108. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000;74(20):9771–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20(5):741–9.

    Article  PubMed  Google Scholar 

  110. Konrad BP, Taylor D, Conway JM, Ogilvie GS, Coombs D. On the duration of the period between exposure to HIV and detectable infection. Epidemics. 2017;20:73–83.

    Article  PubMed  Google Scholar 

  111. CDC. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2018. https://stacks.cdc.gov/view/cdc/23447/cdc_23447_DS1.pdf.

  112. CDC. HIV infection: detection, counseling, and referral—2015 STD treatment guidelines. 2018. https://www.cdc.gov/std/tg2015/hiv.htm.

  113. Braun DL, Kouyos RD, Balmer B, Grube C, Weber R, Günthard HF. Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection. Clin Infect Dis. 2015;61(6):1013–21.

    Article  CAS  PubMed  Google Scholar 

  114. Institute NA. Post-testing counseling, notification, and domestic violence screening. 2013. https://www.hivguidelines.org/adult-hiv/testing-diagnosis/provider-guide-to-hiv-testing-quick-reference-card/.

  115. Clark JL, Perez-Brumer AG, Segura ER, Salvatierra HJ, Sanchez J, Lama JR. Anticipated notification of sexual partners following STD diagnosis among men who have sex with men and transgender women in Lima, Peru: a mixed methods analysis. PLoS ONE. 2016;11(9):e0163905.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  116. Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med. 2014;47(1):5–16.

    Article  PubMed  Google Scholar 

  117. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis: An Official Publication of the Infectious Diseases Society of America. 2011;52(6):793–800.

    Article  Google Scholar 

  118. WHO. Global cascade of care, 2016. 2016. http://www.who.int/hiv/data/en/.

  119. Jalil EM, Wilson EC, Luz PM, et al. HIV testing and the care continuum among transgender women: population estimates from Rio de Janeiro, Brazil. J Int AIDS Soc. 2017;20(1):21873.

    Article  PubMed  PubMed Central  Google Scholar 

  120. NYDOH. HIV among people identified as transgender in New York City, 2012–2016. 2017. http://www1.nyc.gov/site/doh/data/data-sets/epi-surveillance-slide-sets.page.

  121. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–91.

    Article  CAS  Google Scholar 

  122. USDHHS. A timeline of HIV and AIDS. 2016. https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline.

  123. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.

    Article  CAS  Google Scholar 

  124. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–9.

    Article  CAS  PubMed  Google Scholar 

  125. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des. 2004;10(32):4039–53.

    Article  CAS  PubMed  Google Scholar 

  126. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. IAPAC Mon. Apr 2002;8(6):168–75.

    Google Scholar 

  127. Richardson ET, Grant PM, Zolopa AR. Evolution of HIV treatment guidelines in high and low-income countries: converging recommendations. Antiviral Res. 2014;103:88–93.

    Article  CAS  PubMed  Google Scholar 

  128. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.

    Article  CAS  PubMed  Google Scholar 

  129. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853–60.

    Article  Google Scholar 

  130. Wilson EMP, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev. 2013;254(1):343–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.

    Article  CAS  PubMed  Google Scholar 

  132. Borges AH, Neuhaus J, Babiker AG, et al. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. Clin Infect Dis: An Official Publication of the Infectious Diseases Society of America. 2016;63(12):1668–76.

    Article  CAS  Google Scholar 

  133. Silverberg MJ, Abrams DI. Do antiretrovirals reduce the risk of non-aids defining malignancies? Curr Opin HIV AIDS. 2009;4(1):42–51.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–9.

    Article  PubMed  Google Scholar 

  135. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (London, England). 2010;24(1):123–37.

    Google Scholar 

  136. Mayer KH. Antiretroviral therapy for HIV prevention: present status and future prospects. Am J Public Health. 2010;100(10):1867–76.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Mayer KH, Grinsztejn B, El-Sadr WM. Transgender people and HIV prevention: what we know and what we need to know, a call to action. J Acquir Immune Defic Syndr (1999). 2016;72(Suppl 3):S207–9.

    Article  PubMed  Google Scholar 

  139. USDHHS. The HIV life cycle. 2017. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/73/the-hiv-life-cycle.

  140. Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16(1).

    Article  PubMed Central  Google Scholar 

  141. FDA. FDA-approved HIV medicines. 2018. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines.

  142. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother. 2011;55(5):1831–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. WHO guidelines approved by the guidelines review committee. In: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization Copyright (c) World Health Organization 2016; 2016.

    Google Scholar 

  144. Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316(2):191–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. HHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2017. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start.

  146. Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. J Int AIDS Soc. 2016;19(3 Suppl 2):20810.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Sellers CJ, Wohl DA. Antiretroviral therapy: when to start. Infect Dis Clin North Am. 2014;28(3):403–20.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Pacifici GM, Gucci A, Giuliani L. Testosterone sulphation and glucuronidation in the human liver: interindividual variability. Eur J Drug Metab Pharmacokinet. 1997;22(3):253–8.

    Article  CAS  PubMed  Google Scholar 

  149. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDs. 2005;19(10):655–71.

    Article  PubMed  Google Scholar 

  150. Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR network of integrated clinical systems. AIDS (London, England). 2015;29(1):77–81.

    Article  CAS  Google Scholar 

  151. Blick G. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Postgrad Med. 2013;125(2):30–9.

    Article  PubMed  Google Scholar 

  152. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(9):3132–54.

    Article  CAS  Google Scholar 

  153. Wansom T, Guadamuz TE, Vasan S. Transgender populations and HIV: unique risks, challenges and opportunities. J Virus Eradication. 2016;2(2):87–93.

    Article  Google Scholar 

  154. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH. Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001;22(2):148–54.

    CAS  PubMed  Google Scholar 

  155. Aweeka FT, Rosenkranz SL, Segal Y, et al. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS (London, England). 2006;20(14):1833–41.

    Article  CAS  Google Scholar 

  156. Zhang M, Huang Q, Huang Y, et al. Beta-estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL. Retrovirology. 2008;5(1):82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  157. Ho JY, Chen MJ, Sheu WH, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod (Oxford, England). 2006;21(10):2715–20.

    Article  CAS  Google Scholar 

  158. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003;43(5):443–69.

    Article  CAS  PubMed  Google Scholar 

  159. Larder B. Mechanisms of HIV-1 drug resistance. AIDS (London, England). 2001;15:S27–34.

    Article  CAS  Google Scholar 

  160. Sevelius JM, Carrico A, Johnson MO. Antiretroviral therapy adherence among transgender women living with HIV. J Assoc Nurses AIDS Care JANAC. 2010;21(3):256–64.

    Article  PubMed  Google Scholar 

  161. Baguso GN, Gay CL, Lee KA. Medication adherence among transgender women living with HIV. AIDS Care. 2016;28(8):976–81.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Wiewel EW, Torian LV, Merchant P, Braunstein SL, Shepard CW. HIV diagnoses and care among transgender persons and comparison with men who have sex with men: New York City, 2006–2011. Am J Public Health. 2016;106(3):497–502.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Lenox Hill Hospital, Northwell Health, New York, NY, USA

    Ladan Ahmadi, Angelica Nocerino & Daniel Puneky

Authors
  1. Ladan Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelica Nocerino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Puneky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ladan Ahmadi .

Editor information

Editors and Affiliations

  1. Friedman Transgender Health and Wellness Program, Division of Endocrinology, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA

    Leonid Poretsky

  2. Columbia University, New York, NY, USA

    Wylie C. Hembree

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ahmadi, L., Nocerino, A., Puneky, D. (2019). HIV Infection in Transgender Persons. In: Poretsky, L., Hembree, W. (eds) Transgender Medicine. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-030-05683-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-05683-4_13

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-030-05682-7

  • Online ISBN: 978-3-030-05683-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation